newsfilter
← Latest News
GlobeNewswire·

Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist

  • Biomea Fusion, Inc. (NASDAQ: BMEA) will report Phase I GLP-131 clinical study results for its investigational oral small-molecule GLP-1 receptor agonist, BMF-650.
  • The results announcement is scheduled for Tuesday, October 13, 2026.
  • A conference call & webcast to discuss the findings will begin at 4:30 p.m. ET (1:30 p.m. PT).
  • The live webcast will be accessible via the Investors & Media section of Biomea's website, with a replay available post-event.
  • Biomea Fusion is a clinical-stage company developing oral therapies icovamenib & BMF-650 for diabetes & obesity.